Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.33 |
| ▸ | MAP3K8 | P41279 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PRKDC | P78527 | 3/20 | 0.32 |
| ▸ | TNKS | O95271 | 1/20 | 0.31 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.31 |
| ▸ | F9 | P00740 | 1/20 | 0.31 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23770482 | 0.98 | ALOX5 (0.43) | ALOX5PARP14MAP3K8MAPTPRKDC | |
| SCHEMBL23770373 | 0.98 | ALOX5 (0.42) | ALOX5PARP14MAP3K8MAPTPRKDC | |
| SCHEMBL23770468 | 0.97 | ALOX5 (0.44) | ALOX5PARP14MAPTPRKDCTNKS | |
| SCHEMBL23770481 | 0.97 | ALOX5 (0.41) | ALOX5PARP14MAPTPRKDCTNKS | |
| SCHEMBL23770483 | 0.97 | ALOX5 (0.44) | ALOX5PARP14MAP3K8MAPTPRKDC | |
| SCHEMBL23770309 | 0.97 | ALOX5 (0.43) | ALOX5PARP14MAPTPRKDCTNKS | |
| SCHEMBL23770308 | 0.96 | ALOX5 (0.41) | ALOX5PARP14MAPTPRKDCF9 | |
| SCHEMBL25144938 | 0.96 | ALOX5 (0.41) | ALOX5PARP14MAPTPRKDCF9 | |
| SCHEMBL23770476 | 0.96 | ALOX5 (0.41) | ALOX5PARP14MAPTPRKDCF9 | |
| SCHEMBL23770421 | 0.96 | ALOX5 (0.41) | ALOX5PARP14MAPTPRKDCF9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230123170-A1 | COMPOUND, MATERIAL FOR AN ORGANIC ELECTROLUMINESCENCE DEVICE AND AN ORGANIC ELECTROLUMINESCENCE DEVICE COMPRISING THE COMPOUND | IDEMITSU KOSAN CO.,LTD. (JP) | 2023-04-20 | — | — | US | disclosed |
| WO-2021162122-A1 | COMPOUND, MATERIAL FOR AN ORGANIC ELECTROLUMINESCENCE DEVICE AND AN ORGANIC ELECTROLUMINESCENCE DEVICE COMPRISING THE COMPOUND | IDEMITSU KOSAN CO., LTD. (JP) | 2021-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230123170-A1 | COMPOUND, MATERIAL FOR AN ORGANIC ELECTROLUMINESCENCE DEVICE AND AN ORGANIC ELECTROLUMINESCENCE DEVICE COMPRISING THE COMPOUND | L1CAM, LEF1, CCNL2 | ALOX5 1852/4885PARP14 2731/4885MAP3K8 2879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.